Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia

PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Chihara, Dai, Arons, Evgeny, Stetler-Stevenson, Maryalice, Yuan, Constance M., Wang, Hao-Wei, Zhou, Hong, Raffeld, Mark, Xi, Liqiang, Steinberg, Seth M., Feurtado, Julie, James, Lacey, Wilson, Wyndham, Braylan, Raul C., Calvo, Katherine R., Maric, Irina, Dulau-Florea, Alina, Kreitman, Robert J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2020
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213585/
https://ncbi.nlm.nih.gov/pubmed/32109194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02250
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg